- Home
- NNAVW vs SNY Comparison
NNAVW vs SNY Comparison
Compare NNAVW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.20
HOLD
Current Price
$48.75
Company Overview
Basic Information| Metric | NNAVW | SNY |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | France |
| Employees | 96 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NNAVW | SNY |
|---|---|---|
| Price | $7.20 | $48.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.50 |
| AVG Volume (30 Days) | 53.1K | ★ 2.5M |
| Earning Date | 03-12-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | $4,963,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $6.47 |
| P/E Ratio | ★ N/A | $5.64 |
| Revenue Growth | ★ 43.44 | N/A |
| 52 Week Low | $4.47 | $44.62 |
| 52 Week High | $4.70 | $60.12 |
Technical Indicators
Market Signals| Indicator | NNAVW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 72.26 | 44.64 |
| Support Level | $5.25 | $47.80 |
| Resistance Level | $6.00 | $49.73 |
| Average True Range (ATR) | 0.44 | 0.63 |
| MACD | 0.21 | -0.19 |
| Stochastic Oscillator | 89.75 | 36.01 |
Price Performance
Historical Comparison NNAVW
SNY
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.